DCC5268 |
Tulobuterol Hydrochloride |
Long-acting beta2-adrenergic receptor agonist |
|
DCC5269 |
tumor Metastasis Blocker 5k |
Novel Inhibitor of Metastatic Cancer Cell Migration and Invasion |
|
DCC5270 |
Tunicamycin |
Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR) |
|
DCC5271 |
Turneroic Acid |
Inhibitor of bacterial biofilm formation in Staphylococcus epidermidis |
|
DCC5272 |
Tutuilamide A |
Natural potent porcine pancreatic elastase (PPE) inhibitor |
|
DCC5273 |
Txa1 Hydrochloride |
Novel anticancer agent, affecting steroid biosynthesis, increasing RagD expression, and causing abnormal cellular cholesterol localization |
|
DCC5274 |
Txa-709 |
Novel disruptor of the bacterial protein, FtsZ |
|
DCC5275 |
Ty-51469 |
Chymase inhibitor, preventing the development and progression of non-alcoholic steatohepatitis, improving vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats |
|
DCC5276 |
Tyk2 Jh2-in-48 |
Novel highly potent and selective TYK2 JH2 inhibitor, providing robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model |
|
DCC5277 |
Bll5 Maleate |
First-in-class selective PRMT5 inhibitor, blocking EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected |
|
DCC5278 |
Tyr(po(nme2)2 |
Stable analog of phosphotyrosine (pTyr) |
|
DCC5279 |
Tyrosinase Inhibitor Thio-2 |
Novel competitive inhibitor of tyrosinase enzyme |
|
DCC5280 |
U-101958 Maleate [224170-09-6] |
Potent and selective dopamine D4 receptor antagonist |
|
DCC5281 |
Ua62784 |
Novel potent inhibitor of microtubule polymerization, binding directly to tubulin α/β heterodimers via the colchicine-binding site, perturbing mitotic spindles, delaying cells in mitosis and promotes apoptosis |
|
DCC5282 |
Uawj172 |
Novel potent and broad-spectrum antiviral agent against multiple strains of EV-D68, EV-A71, and CVB3, targeting the viral protein 2C |
|
DCC5283 |
Ubp512 |
Selective modulator of NMDA_receptor>NMDA receptors, potentiates responses at GluN1/GluN2A |
|
DCC5284 |
Ubp618 |
Novel pan-inhibitor of GluN1/GluN2 receptors |
|
DCC5285 |
Ubp646 |
Novel pan potentiator of GluN1/GluN2 receptors |
|
DCC5286 |
Ubp684 |
Novel NMDAR positive allosteric modulator (PAM), robustly potentiating responses at all GluN1/GluN2 subtypes and at neuronal NMDARs |
|
DCC5287 |
Ubtr008295a |
Novel Antagonist of the USP5 Zinc Finger Ubiquitin-Binding Domain (USP5 ZnF-UBD) |
|
DCC5288 |
Ucb-11056 |
Modulator of cyclic AMP generation, amplifing induced cyclic AMP formation in rat brain tissue; Nootropic |
|
DCC5289 |
ucb30889 |
Potent ligand of synaptic vesicle protein 2A (SV2A) |
|
DCC5290 |
Ucb-6786 |
Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
DCC5291 |
Ucb-6876 |
Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
DCC5292 |
Ucb-fcrn-303 |
Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn |
|
DCC5293 |
uc-ddc-918013 |
Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
DCC5294 |
uc-ddc-931126 |
Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
DCC5295 |
uc-ddc-966791 |
Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate |
|
DCC5297 |
Uck2-in-135546734 |
Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
DCC5298 |
Uck2-in-135546812 |
Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|